Skip to main content
Premium Trial:

Request an Annual Quote

GeneDx to Raise $150M in Public and Direct Stock Offerings

NEW YORK – GeneDx said Friday that it is selling a combined 428,571,429 shares of its common stock at $.35 per share in an underwritten public offering and concurrent registered direct offering expected to bring in $150 million in gross proceeds.

The public offering consists of 328,571,429 shares, with another 100 million shares being offered directly to "institutional investors affiliated with a member of GeneDx's board of directors." 

Among the 100 million shares being sold directly, 77,663,376 comprise an initial offering, which are expected to be issued following the closing of the public underwritten offering. Another 22,336,624 shares are subject to stockholder approval to satisfy Nasdaq requirements.

Jefferies is acting as the sole bookrunning manager for the underwritten public offering and as the sole placement agent for the direct offering. Cowen is acting as a financial adviser to the company.

GeneDx said it intends to use the net proceeds for general corporate purposes, including additions to working capital, repayment of debts, and strategic investment.

Both the underwritten offering and the initial direct offering are expected to close on or about Jan. 31.

Sema4 acquired GeneDx in April and rebranded itself as GeneDx earlier this month.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.